comprehensive -WSS

comprehensive

author：fashion 2025-09-30 11:07:16 - browse：721

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： CDC's new outbreak response network to include Northeastern

WSS

The inclusion problem at the heart of rehabilitation research

HPV vaccine, cervical cancer study delivers historic results

Head of FDA's diagnostics center, who led through Covid, retires

It's been 20 years since Dolly the sheep. Where's my clone?

Maisha Meds is a PBM, but don't call it that

focus

comprehensive

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Virtual Event: Putting AI to the Test

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Printout prescription drug information shouldn’t go digital

Sports medicine is finally prioritizing gender equality

Dog Aging Project founders on what lies ahead after losing funding

What does generative AI mean for health care? We asked experts

Experts study whether long Covid risk adds up with each reinfection

United colonoscopy coverage change 'may cost lives,' doctors say

Head of FDA's diagnostics center, who led through Covid, retires

hotspot

Mass General, Mayo Clinic look to monetize custom

Experts study whether long Covid risk adds up with each reinfection

Dog Aging Project founders on what lies ahead after losing funding

TikTok, Instagram influencers need more rules for drug ads

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

STAT Virtual Event: Putting AI to the Test

hotspot

entertainment

entertainment

explore